checkAd

     237  0 Kommentare Axsome Therapeutics Announces Proposed Public Offering of Common Stock - Seite 2

    Forward Looking Statements

    Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the anticipated final terms, timing and completion of the proposed offering; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

    Axsome Contact:
    Mark Jacobson
    Senior Vice President, Operations
    Axsome Therapeutics, Inc.
    200 Broadway, 3rd Floor
    New York, NY 10038
    Tel: 212-332-3243
    Email: mjacobson@axsome.com
    www.axsome.com

    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Axsome Therapeutics Announces Proposed Public Offering of Common Stock - Seite 2 NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, …